EHA 2022 | The role of MRD in decision-making in CLL
Peter Hillmen
• 10 Jun 2022
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Apellis Pharmaceuticals, Leeds, UK, talks on the role of measurable residual disease (MRD) in decision-making in chronic lymphocytic leukemia (CLL). Whilst MRD has been used as a key endpoint in many clinical trials, no real-world evidence is indicating that MRD should be used to guide therapy in CLL. According to Prof. Hillmen, in the future, MRD will be used as a tool to define the duration of therapy and to predict outcomes in clinical practice. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
